Corvus Pharmaceuticals, Inc. — Director's Dealing 2022

Aug 15, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Corvus Pharmaceuticals, Inc. (CRVS)
CIK: 0001626971
Period of Report: 2022-08-11

Reporting Person: Mitchell Edith P. (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-08-11	Stock Option (Right to Buy)	$0.9650	A	15000	Acquired	2032-08-11	Common Stock (15000)	Direct

Footnotes

F1: The underlying shares subject to the option vest and become exercisable as to one-twelfth (1/12th) of the shares subject to the option in successive, equal monthly installments measured from August 11, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.